GSK-3
Author: Karolina Kujawa
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
GSK-3 is a 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine, which also includes the conserved, unconjugated pneumococcal proteins dPly and PhtD. dPly is a thiol-dependent toxin, while PhtD is a protein which is exposed on the surface of intact bacteria, and vaccines based on these proteins have the potential to provide broader protection against pneumococcal disease.
Analyst Outlook
GSK-3’s (10-valent recombinant-conjugate pneumococcal vaccine; GlaxoSmithKline) novel vaccine approach and potential for broader
coverage will make it a strong contender on the market, but it will face significant competition from Prevnar 13 (13-valent
pneumococcal conjugate vaccine; Pfizer), as well as pipeline vaccines V114 (15-valent pneumococcal conjugate vaccine; Merck & Co)
and PF-06482077 (20-valent pneumococcal conjugate vaccine; Pfizer), which also aim to provide broader protection.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 GSK-3 : Pneumococcal vaccines
LIST OF TABLES
6 Table 1: GSK-3 drug profile
7 Table 2: Trials of GSK-3 for pneumococcal vaccination
9 Table 3: GSK-3 for pneumococcal vaccination – SWOT analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
2018 ASH Pulse Survey 
Sign up to the